If your prescriber just wrote your first GLP-1 script, you’re starting in a very different year than someone who began in 2023. Coverage widened. Cash prices fell. And the medications themselves (Wegovy, Zepbound, Ozempic, Mounjaro, and the rest) are no longer a niche prescription. This guide is the plain-language version of what to expect: what you’ll pay, how the paperwork works, and what the first month actually feels like.
Not medical advice. This is general information for people starting GLP-1 therapy. Your prescriber decides what’s right for you. Always confirm coverage and cost with your own plan.
What changed in 2026
Three things moved at once this year, and together they pulled a lot of new people into their first prescription.
Coverage got wider. Medicare’s GLP-1 Bridge began on July 1, capping most covered obesity prescriptions at a flat $50/month for Part D enrollees. On the Medicaid side, the CMS BALANCE Model let participating states start covering GLP-1s for obesity, not only for diabetes. The details are in our Medicaid guide.
Cash pricing came down. Both major manufacturers now sell some GLP-1s directly to cash-paying patients through their own pharmacies, at prices well below the old retail list. National pressure on drug pricing pushed in the same direction across 2026. Cash is still the most expensive way to pay, but the gap between “insured” and “paying out of pocket” is narrower than it was.
The lineup filled in. More brands, more doses, and oral options moving through approval mean your prescriber has more to choose from, and more reason to match the medication to your situation rather than reach for whatever’s famous.
None of that tells you your number, though. That depends on which door you came in.
What you’ll actually pay
Your cost is set by how you pay, not by the drug’s sticker price. Here’s the rough map for 2026.
| How you’re covered | What most people pay | Worth knowing |
|---|---|---|
| Commercial insurance + copay card | Often under $100/month | Manufacturer copay cards can knock a covered prescription down sharply; ask your prescriber’s office to apply one |
| Medicare Part D (GLP-1 Bridge) | $50/month for covered obesity drugs | The $50 doesn’t count toward your deductible or the $2,100 out-of-pocket cap — see the Bridge explainer |
| Medicaid (where covered) | Typically $1–$4 | Coverage and prior auth vary by state and by the BALANCE Model |
| Cash / manufacturer-direct | Highest of these | Still usually cheaper than a retail pharmacy’s list price for the same drug |
One honest caveat on the numbers above: coverage rules, copay-card terms, and manufacturer pricing all change through the year. Treat these as starting points and confirm your exact figure with your plan or the manufacturer’s program before you count on it.
The paperwork: prior authorization
Most first prescriptions hit a step called prior authorization, where your insurer has to approve the drug before it covers it. It’s the most common reason a GLP-1 gets delayed, and it’s usually beatable.
Your prescriber’s office typically submits your BMI, your relevant diagnoses, a record of other approaches you’ve tried, and a letter of medical necessity. A complete first submission moves faster than a thin one, so ask whether their office has someone who handles prior auth.
If you’re denied, appeal. The denial has to come in writing with a reason, and many first denials get overturned when the prescriber adds documentation. Don’t treat the first no as the last word.
The first four weeks, honestly
GLP-1s work gradually, and the starting dose is intentionally low to spare you the worst of the side effects. So the first month is your body adjusting, not the scale dropping. Here’s a realistic picture.
Weeks 1–2. Appetite often drops noticeably, or you feel full faster than you’re used to. Nausea is the most common side effect, usually in the day after your injection, and it tends to ease over a few weeks. Mild soreness at the injection site is normal. Some people get tired, a little headachy, or constipated.
Weeks 3–4. Appetite suppression usually settles into something more consistent. Most people lose only a little in the first month, often under a kilo or two, because you’re still on a starter dose. That’s the design working, not the medication failing.
Call your prescriber if you get severe or lasting vomiting, sharp stomach pain, signs of low blood sugar (shaky, sweaty, confused) if you also take insulin or a diabetes drug, or any real change in your vision.
Don’t rush the step-up. The slow titration schedule exists to keep side effects manageable, and pushing it is how people end up miserable enough to quit.
What to track from day one
These drugs work over months. If you’re not measuring, it’s easy to feel like nothing’s happening while the trend is quietly moving the right way. A few things are worth logging from the first injection:
- Weekly weight, same time of day, so you see the trend instead of the daily noise.
- Injection day, site, and dose, which also makes prior-auth renewals painless.
- Side effects in the day or two after each shot, so you and your prescriber can see patterns.
- Hunger and fullness, which tell you whether the dose is doing its job.
Here’s the part a plain checklist misses. Your medication level isn’t steady. Semaglutide’s half-life is about a week, so the drug peaks a couple of days after your shot and tapers before the next one. Lay your side effects and appetite over that curve and the patterns pop: the nausea that always lands the day after your injection, the hunger that returns late in the week as levels fall. That’s the view that turns a titration check-in from guesswork into a real conversation. A dedicated tracker models that curve for your exact medication so you don’t have to.
You don’t have to start alone
The clinical stuff (the dose, the titration, the side effects) belongs with your prescriber. The lived stuff is where other people help. Traqr puts GLP-1 tracking and a moderated peer community in one app, so your doses, weight, and side effects sit next to people on the same medication, sorted by the things that actually come up: side effects, food noise, plateaus, the small wins that aren’t a number on the scale. Every post runs through automated safety checks plus human review, and it’s peer support rather than medical advice, with that reminder built into onboarding. Your private tracking stays separate from anything you choose to share.
Starting a GLP-1 in 2026 is cheaper and better-covered than it was two years ago. Go in knowing your number, expecting a slow first month, and tracking from day one, and you’ll spend less of it guessing.
Traqr supports all eight major GLP-1 and anti-obesity medications. Nothing here is medical advice; confirm coverage with your plan and treatment decisions with your prescriber.